Montelukast for treating seasonal allergic rhinitis: a randomized, double‐blind, placebo‐controlled trial performed in the spring
- 5 July 2002
- journal article
- clinical trial
- Published by Wiley in Clinical and Experimental Allergy
- Vol. 32 (7) , 1020-1028
- https://doi.org/10.1046/j.1365-2222.2002.01422.x
Abstract
Background Cysteinyl leukotrienes are important proinflammatory mediators believed to have a role in allergic rhinitis. Objective This multicentre, randomized, double‐blind, placebo‐ and active‐controlled trial evaluated the effectiveness and tolerability of montelukast, a cysteinyl leukotriene receptor antagonist, for treating patients with seasonal allergic rhinitis. Methods After a 3‐ to 5‐day, single‐blind placebo run‐in period, 1302 male and female patients (aged 15–81 years) with active allergic rhinitis symptoms were randomly assigned to receive montelukast 10 mg (n = 348), loratadine 10 mg (n = 602), or placebo (n = 352) administered once daily at bedtime for 2 weeks during the spring allergy season. Results Mean patient characteristics and symptom scores at baseline were similar for the three treatment groups. The primary end‐point, daytime nasal symptoms score (mean of nasal congestion, rhinorrhea, nasal pruritus, and sneezing scores; 0–3 scale), improved from baseline during treatment by (least squares mean, 95% confidence interval) − 0.37 (− 0.43, − 0.31), − 0.47 (− 0.52, − 0.43), and − 0.24 (− 0.29, − 0.18) in the montelukast, loratadine, and placebo groups, respectively (P ≤ 0.001 comparing each active treatment with placebo). Mean changes from baseline in all other diary‐based scores, including night‐time and eye symptom scores, were significantly greater for each active treatment than for placebo. The rhinoconjunctivitis quality of life overall score improved significantly with montelukast and with loratadine as compared with placebo. Montelukast and loratadine showed a safety profile comparable to that of placebo. Conclusion Montelukast is well tolerated and provides improvements in daytime and night‐time symptoms, as well as quality of life parameters, for patients with seasonal allergic rhinitis.Keywords
This publication has 33 references indexed in Scilit:
- Clinical safety and tolerability of montelukast, a leukotriene receptor antagonist, in controlled clinical trials in patients aged ≥ 6 yearsClinical and Experimental Allergy, 2001
- Effects of monotherapy with intra-nasal corticosteroid or combined oral histamine and leukotriene receptor antagonists in seasonal allergic rhinitisClinical and Experimental Allergy, 2001
- Effects of monotherapy with intra‐nasal corticosteroid or combined oral histamine and leukotriene receptor antagonists in seasonal allergic rhinitisClinical and Experimental Allergy, 2001
- Quality of life in patients with allergic rhinitisAnnals of Allergy, Asthma & Immunology, 2000
- Role for cysteinyl leukotriene receptor antagonist therapy in asthma and their potential role in allergic rhinitis based on the concept of “one linked airway disease”Annals of Allergy, Asthma & Immunology, 2000
- 1131 Combination of montelukast and loratadine in seasonal allergic rhinitis: An analysis of three spring studiesJournal of Allergy and Clinical Immunology, 2000
- Allergic rhinitis and asthma: How important is the link?☆☆☆★Journal of Allergy and Clinical Immunology, 1997
- LoratadineDrugs, 1994
- Immunohistology of the nasal mucosa in seasonal allergic rhinitis: Increases in activated eosinophils and epithelial mast cellsJournal of Allergy and Clinical Immunology, 1992
- Peptide Leukotriene Release after Antigen Challenge in Patients Sensitive to RagweedNew England Journal of Medicine, 1984